JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 4, 2006; DOI: 10.1124/jpet.106.107490


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.107490v1
320/1/437    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, C.
Right arrow Articles by Marek, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, C.
Right arrow Articles by Marek, G. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLYCINE


Received for publication May 12, 2006.
Revised October 2, 2006.
Accepted for publication October 3, 2006.

Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydoxytryptamine2A receptor activation

Ce Zhang 1 Gerard J. Marek 2*

1 Shanxi Medical University 2 Eli Lilly and Company

* Address correspondence to: E-mail: marekgj{at}lilly.com

Abstract

Activation and blockade of prefrontal cortical 5-hydroxytryptamine2A (5-HT2A) receptors has been linked to the action of hallucinogenic and antidepressant/antipsychotic drugs; these effects may involve modulation of glutamate release from thalamocortical afferents. While activation of metabotropic glutamate2 (mGlu2) receptors may suppress 5-HT-induced excitatory postsynaptic currents (EPSCs), group III mGlu receptors (mGlu4/7/8) also are expressed in the thalamus and may suppress 5-HT-induced EPSCs. We have found by intracellular recordings from layer V pyramidal cells of the medial prefrontal cortex (mPFC) that group III mGlu receptor agonists (RS)-4-phosphonophenylglycine (PPG), L-4-phosphono-2-aminobutyric acid (L-AP4), L-serine-O-phosphate (L-SOP), and (S)-2-amino-2-methyl-4-phosphonobutanoic acid (MAP4) preferentially suppress 5-HT-induced EPSCs compared to excitatory postsynaptic potentials (EPSPs) evoked by electrical stimulation of the white matter. A number of pharmacological features (e.g., the rank order of agonist potency; MAP4 partial agonist action; differential potency for the group III mGlu receptor antagonist (RS)-{alpha}-cyclopropyl-4-phosphonophenylglycine (CPPG) in blocking the suppressant action of PPG or MAP4; and a relatively low potency of (2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxyclopropyl)-glycine (LY341495) in blocking the suppressant action of PPG or L-SOP) suggests that activation of both mGlu4 and mGlu8 receptors may play a role in suppressing 5-HT-induced EPSCs. Furthermore, L-SOP did not alter the synaptic currents or steady-state inward current induced by {alpha}-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA). Thus, while both group III and group II mGlu receptor agonists suppress the frequency of 5-HT-induced EPSCs in the mPFC, they differ in that the group III mGlu receptor agonists appear to have relatively minimal effects on glutamate released by sources other than thalamocortical afferents.


Key words: 5-HT2A receptors, mGlu receptors, mGlu4 receptors, mGlu8 receptors, prefrontal cortex, serotonin





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.